URB #426 — The Gold Standard Category Error: Pragmatic Efficacy vs. Mechanistic Attribution in Drug Approval

The randomized, double-blind, placebo-controlled trial (RCT) — "the gold standard of medical evidence" — was designed to answer a specific epistemic question: is the observed effect of an intervention causally attributable to the intervention's pharmacological mechanism rather than to expectation, observer bias, or selection effects? This is the **mechanistic attribution question**. It is a legitimate scientific question. It is, however, a completely different question from the **pragmatic efficacy question**: does this intervention produce net positive outcomes for patients who receive it? Medical regulatory frameworks have systematically conflated these two questions — requiring an affirmative answer to the mechanistic question before permitting access to the pragmatic benefit. The placebo-control criterion for psychedelic research exemplifies this conflation at its most consequential and most perverse: psychedelics cannot be adequately double-blinded because the subjective experience is unmistakable, and this methodological fact is used to indefinitely delay access to treatments that demonstrably help patients. This paper argues that the conflation is a category error — a philosophical error with life-and-death consequences — and that the correct epistemic framework separates pragmatic and mechanistic questions, answers each with appropriate methods, and permits pragmatic access on pragmatic evidence without requiring mechanistic certainty as a precondition.